Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
基本信息
- 批准号:9327104
- 负责人:
- 金额:$ 42.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnimalsBindingBiologicalBiopsyCaliberCancer BiologyCancer EtiologyCancer PatientCarcinomaCessation of lifeChelating AgentsClinicClinicalClinical DataClinical ManagementContrast MediaDetectionDevelopmentDiagnosisDiagnostic ImagingDiagnostic ProcedureDifferential DiagnosisDiseaseDisease ManagementDrug KineticsEarly DiagnosisEconomicsEffectivenessEventExcretory functionExtracellular MatrixFibronectinsGoalsHumanImageryImaging DeviceImaging TechniquesImaging technologyIndolentInterventionLeadMagnetic Resonance ImagingMalignant neoplasm of prostateMedicalMicrometastasisModelingMolecularMusNeoplasm MetastasisNormal tissue morphologyOncoproteinsPathologyPatient CarePatientsPeptidesPhysiciansPhysicsPhysiologicalPositron-Emission TomographyProstateProstate Cancer therapyProstate-Specific AntigenProstatic NeoplasmsResearchResolutionRiskRisk stratificationSafetySignal TransductionSpecimenTestingTimeTissuesToxic effectTumor TissueTumor-DerivedUltrasonographyUniversitiesangiogenesiscancer cellchelationclinical applicationclinical developmentclinical practiceclinical translationcontrast enhancedcost effectiveefficacy testingepithelial to mesenchymal transitionexperimental studyhigh riskimage guided therapyimaging agentimaging approachimmunogenicityimprovedin vivointerdisciplinary approachmenmolecular imagingmortalitymouse modelnon-invasive imagingnoveloncologyoutcome forecastoverexpressionpreclinical developmentpreclinical evaluationpreventprostate biopsyprotein biomarkerssafety testingscreeningsocialstemnesssuccesstooltumor
项目摘要
Abstract
The goal of this project is to develop a safe and effective targeted MRI contrast agent for accurate
early detection and differential diagnosis of high-risk prostate cancer. Prostate cancer is a highly
heterogeneous disease and the second most cause of cancer death of men in the US. Early accurate
detection and differential diagnosis of high-risk prostate cancer are critical for physicians to tailor
efficacious interventions to treat the disease earlier at a treatable stage. We propose to develop a novel
molecular imaging approach that targets an oncoprotein associated with epithelial-to-mesenchymal
transition (EMT), cancer cell stemness, angiogenesis, proliferation, and metastasis. The oncoprotein has
a high expression in the tumor extracellular matrix of high-risk prostate cancer, low in low grade tumor,
none in normal tissues. Non-invasive high-resolution MRI of the oncoprotein holds a great promise for
accurate localization and differential diagnosis of high-risk prostate cancer. The specific aims of the
project are 1) to optimize peptide-targeted MRI contrast agents specific to the oncoprotein in high-risk
prostate cancer and to establish mouse prostate PDX models; 2) to perform preclinical evaluation of the
targeted MRI contrast agents; 3) to determine the effectiveness of the targeted MRI contrast agents for
early detection and differential diagnosis of high-risk prostate cancer in animal tumor models, including
patient-derived tumor models, and the toxicity of a lead targeted contrast agent. We have demonstrated
the feasibility of our targeted contrast agents in detection and differential prognosis of high-risk prostate
cancer in animal models. Multidisciplinary approaches will be applied by a strong research team with
complementary expertise in molecular imaging, uro-oncology, pathology, cancer biology, and MRI
physics from Case Western Reserve University and Cleveland Clinic in this project. We will identify a
lead targeted contrast agent to initiate comprehensive preclinical and clinical development. The targeted
contrast agent will have the potential to provide early detection, localization, and differential diagnosis of
high-risk prostate cancer. It can also be used for risk stratification, active surveillance, and image-guide
therapy of prostate cancer in clinical practice. Success in this endeavor is not limited to better clinical
management of the disease, but will also provide exceptional economic and social benefit.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHENG-RONG LU其他文献
ZHENG-RONG LU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHENG-RONG LU', 18)}}的其他基金
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10307922 - 财政年份:2021
- 资助金额:
$ 42.34万 - 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10300425 - 财政年份:2018
- 资助金额:
$ 42.34万 - 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10524128 - 财政年份:2018
- 资助金额:
$ 42.34万 - 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10755865 - 财政年份:2018
- 资助金额:
$ 42.34万 - 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10532735 - 财政年份:2018
- 资助金额:
$ 42.34万 - 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
- 批准号:
10054176 - 财政年份:2018
- 资助金额:
$ 42.34万 - 项目类别:
Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
- 批准号:
9903251 - 财政年份:2017
- 资助金额:
$ 42.34万 - 项目类别:
Image-guided EMT inhibition for treating metastatic breast cancer
图像引导 EMT 抑制治疗转移性乳腺癌
- 批准号:
9301500 - 财政年份:2015
- 资助金额:
$ 42.34万 - 项目类别:
Biodegradable macromolecular CT contrast agents
可生物降解高分子CT造影剂
- 批准号:
8790640 - 财政年份:2014
- 资助金额:
$ 42.34万 - 项目类别:
Biodegradable macromolecular CT contrast agents
可生物降解高分子CT造影剂
- 批准号:
8870352 - 财政年份:2014
- 资助金额:
$ 42.34万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 42.34万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 42.34万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 42.34万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 42.34万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 42.34万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)